NASDAQ:ALLOAllogene Therapeutics Stock Price, Forecast & News

Allogene Therapeutics' stock was trading at $25.05 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ALLO stock has increased by 97.0% and is now trading at $49.35. View which stocks have been most impacted by Coronavirus.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allogene Therapeutics in the last year. There are currently 4 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Allogene Therapeutics.

Allogene Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Allogene Therapeutics.

Allogene Therapeutics Inc (NASDAQ:ALLO) posted its quarterly earnings data on Wednesday, May, 6th. The company reported ($0.58) earnings per share for the quarter, hitting the Zacks' consensus estimate of ($0.58). View Allogene Therapeutics' earnings history.

13 brokers have issued 12 month target prices for Allogene Therapeutics' shares. Their forecasts range from $27.00 to $60.00. On average, they anticipate Allogene Therapeutics' stock price to reach $39.09 in the next year. This suggests that the stock has a possible downside of 20.8%. View analysts' price targets for Allogene Therapeutics.

Media stories about ALLO stock have trended positive recently, InfoTrie Sentiment reports. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Allogene Therapeutics earned a media sentiment score of 2.7 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 2.0 out of 10, meaning that recent media coverage is very unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutAllogene Therapeutics.

Allogene Therapeutics saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 13,170,000 shares, a decrease of 6.7% from the April 30th total of 14,110,000 shares. Based on an average trading volume of 758,900 shares, the days-to-cover ratio is presently 17.4 days. Currently, 26.0% of the company's shares are sold short. View Allogene Therapeutics' Current Options Chain.

Some companies that are related to Allogene Therapeutics include Seattle Genetics (SGEN), Moderna (MRNA), NOVOZYMES A/S/S (NVZMY), Neurocrine Biosciences (NBIX), BioNTech (BNTX), BIO-TECHNE (TECH), Qiagen (QGEN), Repligen (RGEN), argenx (ARGX), Acceleron Pharma (XLRN), Adaptive Biotechnologies (ADPT), Iovance Biotherapeutics (IOVA), Spark Therapeutics (ONCE), Crispr Therapeutics (CRSP) and China Biologic Products (CBPO). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Allogene Therapeutics investors own include Advanced Micro Devices (AMD), Crispr Therapeutics (CRSP), NVIDIA (NVDA), Teladoc Health (TDOC), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Inovio Pharmaceuticals (INO), Alibaba Group (BABA), bluebird bio (BLUE) and Sorrento Therapeutics (SRNE).

(ALLO) raised $272 million in an initial public offering (IPO) on Thursday, October 11th 2018. The company issued 16,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Jefferies acted as the underwriters for the IPO.

Allogene Therapeutics trades on the NASDAQ under the ticker symbol "ALLO."

Allogene Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Capital Research Global Investors (7.16%), BlackRock Inc. (3.91%), Capital International Investors (3.65%), VV Manager LLC (1.83%), Alliancebernstein L.P. (1.58%) and State Street Corp (1.35%). Company insiders that own Allogene Therapeutics stock include Alison Moore, Arie Belldegrun, David D Chang, Eric Thomas Schmidt and Group Holdings (Sbs) Advis Tpg. View institutional ownership trends for Allogene Therapeutics.

ALLO stock was sold by a variety of institutional investors in the last quarter, including VV Manager LLC, BlackRock Inc., Russell Investments Group Ltd., Morgan Stanley, Coastal Bridge Advisors LLC, Shikiar Asset Management Inc., Deutsche Bank AG, and Victory Capital Management Inc.. Company insiders that have sold Allogene Therapeutics company stock in the last year include Alison Moore, David D Chang, and Eric Thomas Schmidt. View insider buying and selling activity for Allogene Therapeutics.

ALLO stock was purchased by a variety of institutional investors in the last quarter, including Capital Research Global Investors, Capital International Investors, Casdin Capital LLC, Rock Springs Capital Management LP, Eaton Vance Management, Alliancebernstein L.P., Tekla Capital Management LLC, and Wildcat Capital Management LLC. Company insiders that have bought Allogene Therapeutics stock in the last two years include Arie Belldegrun, David D Chang, and Group Holdings (Sbs) Advis Tpg. View insider buying and selling activity for Allogene Therapeutics.

Shares of ALLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ALLO stock can currently be purchased for approximately $49.35.

Allogene Therapeutics has a market capitalization of $6.19 billion. The company earns $-184,590,000.00 in net income (profit) each year or ($1.83) on an earnings per share basis. Allogene Therapeutics employs 122 workers across the globe.

The official website for Allogene Therapeutics is www.allogene.com.

Allogene Therapeutics' mailing address is 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-457-2700 or via email at [email protected]